NCT00792805 - Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

563

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Indacaterol 150 µg

Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

DRUG

Indacaterol 300 μg

Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

DRUG

Placebo to indacaterol

Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

Trial Locations (15)

Novartis Investigative Site, Adelaide

Novartis Investigative Site, Clayton

Novartis Investigative Site, Daw Park

Novartis Investigative Site, Beijing

Novartis Investigative Site, Changsha

Novartis Investigative Site, Chongqing

Novartis Investigator Site, Fuzhou

Novartis Investigative Site, Guangzhou

Novartis Investigative Site, Shandong

Novartis Investigative Site, Shanghai

Novartis Investigative Site, Shenyang

Novartis Investigative Site, Shijiazhuang

Novartis Investigative Site, Xi'an

Novartis Investigative Site, Bangalore

Novartis Investigative Site, Trivandrum